TY - JOUR
T1 - Serotonin enhances oxybuprocaine- and proxymetacaine-induced cutaneous analgesia in rats
AU - Chou, An Kuo
AU - Chiu, Chong Chi
AU - Wang, Jhi Joung
AU - Chen, Yu Wen
AU - Hung, Ching Hsia
N1 - Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/3/5
Y1 - 2019/3/5
N2 - The aim of the study was to investigate the analgesic effects of adding serotonin to oxybuprocaine or proxymetacaine preparations. We employed a rat model of the cutaneous trunci muscle reflex (CTMR) to conduct the dose-response curves and duration of drugs (oxybuprocaine, proxymetacaine, or serotonin) as an infiltrative anesthetic. The use of isobolographic methods to analyze the drug-drug interactions. We showed that oxybuprocaine and proxymetacaine, as well as serotonin produced dose-dependent skin antinociception. On the basis of 50% effective dose (ED50), the rank order of drug potency was serotonin [7.22 (6.45–8.09) μmol/kg] < oxybuprocaine [1.03 (0.93–1.15) μmol/kg] < proxymetacaine [0.59 (0.53–0.66) μmol/kg] (P < 0.01 for each comparison). The sensory block duration of serotonin was longer (P < 0.01) than that of oxybuprocaine or proxymetacaine at the equipotent doses (ED25, ED50, and ED75). The mixture of serotonin with oxybuprocaine or proxymetacaine produced a better analgesic effect than the drug itself. We have concluded that oxybuprocaine, proxymetacaine, or serotonin displays dose-related cutaneous analgesia. Oxybuprocaine or proxymetacaine is more potent and has a shorter duration of cutaneous analgesia than serotonin. Serotonin produces a synergistic antinociceptive interaction with oxybuprocaine or proxymetacaine.
AB - The aim of the study was to investigate the analgesic effects of adding serotonin to oxybuprocaine or proxymetacaine preparations. We employed a rat model of the cutaneous trunci muscle reflex (CTMR) to conduct the dose-response curves and duration of drugs (oxybuprocaine, proxymetacaine, or serotonin) as an infiltrative anesthetic. The use of isobolographic methods to analyze the drug-drug interactions. We showed that oxybuprocaine and proxymetacaine, as well as serotonin produced dose-dependent skin antinociception. On the basis of 50% effective dose (ED50), the rank order of drug potency was serotonin [7.22 (6.45–8.09) μmol/kg] < oxybuprocaine [1.03 (0.93–1.15) μmol/kg] < proxymetacaine [0.59 (0.53–0.66) μmol/kg] (P < 0.01 for each comparison). The sensory block duration of serotonin was longer (P < 0.01) than that of oxybuprocaine or proxymetacaine at the equipotent doses (ED25, ED50, and ED75). The mixture of serotonin with oxybuprocaine or proxymetacaine produced a better analgesic effect than the drug itself. We have concluded that oxybuprocaine, proxymetacaine, or serotonin displays dose-related cutaneous analgesia. Oxybuprocaine or proxymetacaine is more potent and has a shorter duration of cutaneous analgesia than serotonin. Serotonin produces a synergistic antinociceptive interaction with oxybuprocaine or proxymetacaine.
UR - http://www.scopus.com/inward/record.url?scp=85060196902&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060196902&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2019.01.009
DO - 10.1016/j.ejphar.2019.01.009
M3 - Article
C2 - 30639797
AN - SCOPUS:85060196902
SN - 0014-2999
VL - 846
SP - 73
EP - 78
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
ER -